Table 1.
Clinical data of the Chilean IBD patients.
| Clinical variable | n = 184 |
|---|---|
| Ulcerative Colitis/Crohn Disease | 138 (75%)/46 (25%) |
| Age, years, median (max–min) | 49 (17-81) |
| Age, years, at diagnoses (median, min-max) | 36 (7–73) |
| Disease Duration, years, (median, min-max) | 8 (1–47) |
| Extraintestinal manifestation (no/yes) | 116 (63%)/68 (37%) |
| Hospitalization (no/yes/no data) | 83 (45%)/99 (53.8%)/2 (0.2%) |
| Smoking (no/yes/no data) | 153 (83.2%)/30 (16.3%)/1 (0.5%) |
| Hemoglobin (g/L) | |
| Normal range 12–18, mean (max–min) | 13.84 (8.80–17.60) |
| White cell count × 106/L | |
| Normal range 4000–11000, mean (max–min) | 7138 (2690–16740) |
| Platelets, × 106/L | |
| Normal range 150000–450000, mean (max–min) | 294452 (28000–602000) |
| C reactive protein (mg/dL) | |
| Normal range < 0.5, mean (max–min) | 2.55 (0.03–30) |
| Albumin (g/L) | |
| Normal range (3.5–5.5), mean (max–min) | 4.40 (2.9–5.2) |
| Resective surgery (no/yes) | 156 (85%)/28 (15%) |
| History infection for clostridiodes difficile | |
| (No/yes/no data) | 162 (88%)/20 (11%)/2 (1%) |
| Current use of steroids (no/yes) | 151 (82%)/33 (18%) |
| Anti-TNFa use (no/yes) | 152 (83%)/32 (17%) |
| Thiopurines/Inmunosupresor use | 116 (63%)/68 (37%) |
| Naïve anti TNFa (no/yes) | 38 (21%)/146 (79%) |
| Montreal ulcerative colitis (N = 138) | |
| Extensive colitis (E3) | 48 (35%) |
| Left colitis (E2) | 43 (31%) |
| Proctitis (E1) | 34 (24.6%) |
| No registered | 13 (9.4%) |
| Montreal Crohn's disease (n = 46) | |
| Age | |
| A1/A2/A3/No registered | 2 (4%)/21 (46%)/22 (48%)/1 (2%) |
| Localization | |
| Ileal (L1) | 6 (13%) |
| Colonic (L2) | 21 (45.7%) |
| Ileocolonic (L3) | 16 (34.8% |
| No data | 3 (6.5%) |
| Upper compromise (L4) (no/yes/no registered) | 40 (87%)/ 5 (11%)/1 (2%) |
| Behavior | |
| B1 (inflammatory) | 15 (33%) |
| B2 (structuring) | 11 (24%) |
| B3 (penetrating) | 17 (37%) |
| No registered | 3 (6%) |
| Perianal disease (yes/no) | 25 (54%)/21 (46%) |
Anti-Tumor Necrosis Factor alpha = Anti-TNFa; A1, age at diagnoses Crohn's disease less than < 16 years; A2, age at diagnoses Crohn's disease 17–40 years; A3, age at diagnoses Crohn's Disease more than >40 years.